Hyderabad-based pharma major says US FDA approval likely to come after upcoming audit

Hyderabad-based Aurobindo Pharma Limited is hoping to receive three-four product approvals in the oncology space from the US Food and Drug Administration (US FDA) before March 2018.

The company’s optimistic prediction about a possible good start in this high-margin product business comes just ahead of a maiden audit slated to be conducted for its oncology formulations manufacturing facility by the US drug regulator.

Continue reading